The clinical management of neuromuscular disorders in intensive care

Neuromuscular Disorders

Volumn 29, Issue 2, 2019, Pages 85-96

  Damian, Maxwell S ^a   Wijdicks, Eelco F M ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

Guillain Barr syndrome; ICU acquired weakness; Myasthenic crisis; Myopathy with early respiratory failure; Neuromuscular respiratory mechanics; Rhabdomyolysis

Indexed keywords

CHOLINESTERASE INHIBITOR; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; SUGAMMADEX; TACROLIMUS;

CONGENITAL MYASTHENIC SYNDROME; DIAGNOSTIC PROCEDURE; DRUG PULSE THERAPY; EMERGENCY CARE; GENETIC DISORDER; GUILLAIN BARRE SYNDROME; HEALTH CARE MANAGEMENT; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MYASTHENIA GRAVIS; MYOPATHY; MYOSITIS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NONINVASIVE VENTILATION; PATIENT MONITORING; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; DISEASE MANAGEMENT;

CRITICAL CARE; DISEASE MANAGEMENT; HUMANS; NEUROMUSCULAR DISEASES;

EID: 85059690643     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2018.12.005     Document Type: Review

References (102)

1. Damian, MS, Ben-Shlomo, Y, Howard, R, Bellotti, T, Harrison, D, Griggs, K, et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain–Barré syndrome admitted to critical care: an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 39:8 (2013), 1405–1412.
2. Wijdicks, EFM, The neurology of acutely failing respiratory mechanics. Ann Neurol 81 (2017), 489–498.
3. Winck, JC, LeBlanc, C, Soto, JL, Plano, F, The value of cough peak flow measurements in the assessment of extubation or decannulation readiness. Rev Port Pneumol 21:2 (2006), 94–98 2015.
4. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain–Barré syndrome. Arch Neurol. 200;58(6):893–8.
5. Lawn, ND, Wijdicks, EF, Tracheostomy in Guillain–Barré syndrome. Muscle Nerve 22:8 (1999), 1058–1062.
6. Dugernier, J, Bialais, E, Reychler, G, Vinetti, M, Hantson, P, Neurally adjusted ventilatory assist during weaning from respiratory support in a case of Guillain–Barré syndrome. Respir Care 60:4 (2015), 68–72.
7. Hughes, RA, Wijdicks, EF, Benson, E, Cornblath, DR, Hahn, AF, Meythaler, JM, et al. Multidisciplinary consensus group. Supportive care for patients with Guillain–Barré syndrome. Arch Neurol 62:8 (2005), 1194–1198.
8. Kuitwaard, K, de Gelder, J, Tio-Gillen, AP, Hop, WC, van Gelder, T, van Toorenenbergen, AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain–Barré syndrome. Ann Neurol 66:5 (2009), 597–603.
9. Ortiz-Salas, P, Velez-Van-Meerbeke, A, Galvis-Gomez, CA, Rodriguez Q, JH, Human immunoglobulin versus plasmapheresis in Guillain–Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis 18:1 (2016), 1–11.
10. Pfeiffer, G, Schiller, B, Kruse, J, Netzer, J, Indicators of dysautonomia in severe Guillain–Barré syndrome. J Neurol 246:11 (1999), 1015–1022.
11. Rigamonti, A, Basso, F, Scaccabarozzi, C, Lauria, G, Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain–Barré syndrome: case report and review of the literature. J Peripher Nerv Syst 17:3 (2012), 356–360.
12. Martins, RP, Barbarot, N, Coquerel, N, Baruteau, AE, Kolev, I, Vérin, M, Takotsubo cardiomyopathy associated with Guillain–Barré syndrome: a differential diagnosis from dysautonomia not to be missed. J Neurol Sci 291:1–2 (2010), 100–102.
13. Nguyen, TN, Badjatia, N, Malhotra, A, Gibbons, FK, Qureshi, MM, Greenberg, SA, Factors predicting extubation success in patients with Guillain–Barré syndrome. Neurocrit Care 5:3 (2006), 230–234.
14. Fletcher, DD, Lawn, ND, Wolter, TD, Wijdicks, EF, Long-term outcome in patients with Guillain–Barré syndrome requiring mechanical ventilation. Neurology 54:12 (2007), 2311–2315.
15. Alshekhlee, A, Miles, JD, Katirji, B, Preston, DC, Kaminski, HJ, Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:18 (2009), 1548–1554.
16. Teramoto, K, Kuwabara, M, Matsubara, Y, Respiratory failure due to vocal cord paresis in myasthenia gravis. Respiration 69:3 (2002), 280–282.
17. Dengler, R, Rüdel, R, Warelas, J, Birnberger, KL, Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction. Pflugers Arch 380:2 (1979), 145–151.
18. Chegini, A, Therapeutic plasma exchange in a rare case of myasthenic crisis after Botox injection. Atheroscler Suppl 30 (2017), 283–285.
19. Wolfe, GI, Kaminski, HJ, Aban, IB, Minisman, G, Kuo, HC, Marx, A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:6 (2016), 511–522.
20. Engel, AG, Why does acetylcholine exacerbate myasthenia caused by anti-MuSK antibodies?. J Physiol, 591(10), 2013, 2377.
21. Suzuki, S, Utsugisawa, K, Nagane, Y, Suzuki, N, Three types of striational antibodies in myasthenia gravis. Autoimmune Dis, 2011, 2011, 740583, 10.4061/2011/740583 Epub 2011 Jul 17.
22. Beydoun, SR, Wang, JT, Levine, RL, Farvid, A, Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report. J Med Case Rep, 4, 2010, 393.
23. Finsterer, J, Stöllberger, C, Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome. Int J Cardiol 203 (2016), 616–617.
24. Seneviratne, J, Mandrekar, J, Wijdicks, EF, Rabinstein, AA, Noninvasive ventilation in myasthenic crisis. Arch Neurol 65:1 (2008), 54–58.
25. Seneviratne, J, Mandrekar, J, Wijdicks, EF, Rabinstein, AA, Predictors of extubation failure in myasthenic crisis. Arch Neurol 65 (2008), 929–933.
26. Confavreux, C, Saddier, P, Grimaud, J, Moreau, T, Adeleine, P, Aimard, G, Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:6 (1996), 1607–1612.
27. Nero, P, Rahman, A, Isenberg, DA, Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus?. Ann Rheum Dis 63:3 (2004), 325–326.
28. Besinger, UA, Toyka, KV, Homberg, M, Heininger, K, Hohlfeld, R, Fateh-Moghadam, A, Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:10 (1983), 1316–1321.
29. Burns, TM, Conaway, MR, Cutter, GR, Sanders, DB, Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 38:6 (2008), 1553–1562.
30. Bohan, A, Peter, JB., Polymyositis and dermatomyositis. N Engl J Med 292:7 (1975), 344–347.
31. Hoogendijk, JA, Amato, AA, Lecky, BR, Choy, EH, Lundberg, IE, Rose, MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:5 (2004), 337–345.
32. Tansley, SL, McHugh, NJ, Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep, 16(12), 2014, 464.
33. Albayda, J, Khan, A, Casciola-Rosen, L, Corse, AM, Paik, JJ, Christopher-Stine, L, Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47:4 (2018), 552–556.
34. van de Vlekkert, J, Hoogendijk, JE, de Haan, RJ, Algra, A, van der Tweel, I, van der Pol, WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:6 (2010), 382–389.
35. Allenbach, Y, Benveniste, O, Acquired necrotizing myopathies. Curr Opin Neurol 26:5 (2013), 554–560.
36. Watanabe, Y, Uruha, A, Suzuki, S, Nakahara, J, Hamanaka, K, Takayama, K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87:10 (2016), 1038–1044.
37. Allenbach, Y, Mammen, AL, Benveniste, O, Stenzel, W, Immune-mediated necrotizing myopathies working group. 224th ENMC international workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 28:1 (2018), 87–99.
38. Rosenberg, H, Pollock, N, Schiemann, A, Bulger, T, Stowell, K, Malignant hyperthermia; a review. Orphanet J Rare Dis, 10, 2015, 93.
39. Pedavally, S, Fugate, JE, Rabinstein, AA, Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care 21:1 (2014), 108–113.
40. Scalco, RS, Gardiner, AR, Pitceathly, RD, Zanoteli, E, Becker, J, Holton, JL, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis, 10, 2015, 51.
41. Zutt, R, van der Kooi, AJ, Linthorst, GE, Wanders, RJ, de Visser, M, Rhabdomyolysis: review of the literature. Neuromuscul Disord 24:8 (2014), 651–659.
42. Vivante, A, Ityel, H, Pode-Shakked, B, Chen, J, Shril, S, van der Ven, AT, et al. Exome sequencing in Jewish and Arab patients with rhabdomyolysis reveals single-gene etiology in 43% of cases. Pediatr Nephrol 32:12 (2017), 2273–2282.
43. Di Mauro, S, Muscle glycogenoses: an overview. Acta Myol 26:1 (2007), 35–41.
44. Voermans, NC, Snoeck, M, Jungbluth, H, RYR1-related rhabdomyolysis: a common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunction. Rev Neurol (Paris) 172:10 (2016), 546–558.
45. Anandan, C, Cipriani, MA, Laughlin, RS, Niu, Z, Milone, M, Rhabdomyolysis and fluctuating asymptomatic hyperCKemia associated with CACNA1S variant. Eur J Neurol 25:2 (2017), 417–419.
46. Lévesque, S, Auray-Blais, C, Gravel, E, Boutin, M, Dempsey-Nunez, L, Jacques, PE, et al. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. Orphanet J Rare Dis, 11, 2016, 8.
47. Hottinger, AF, Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29:6 (2016), 806–812.
48. Fernández-Lorente, J, Esteban, A, Salinero, E, Traba, A, Prieto, J, Palencia, E, Critical illness myopathy. Neurophysiological and muscular biopsy assessment in 33 patients. Rev Neurol 50:12 (2010), 718–726.
49. Hermans, G, Van den Berghe, G, Clinical review: intensive care unit acquired weakness. Crit Care, 19, 2015, 274.
50. van Hees, HW, Schellekens, WJ, Linkels, M, Leenders, F, Zoll, J, Donders, R, et al. Plasma from septic shock patients induces loss of muscle protein. Crit Care, 15(5), 2011, R233.
51. Hermans, G, Wilmer, A, Meersseman, W, Milants, I, Wouters, PJ, Bobbaers, H, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Resp Crit Care Med 175:5 (2007), 480–489.
52. Witteveen, E, Wieske, L, van der Poll, T, van der Schaaf, M, van Schaik, IN, Schultz, MJ, et al. Increased early systemic inflammation in ICU-acquired weakness; a prospective observational cohort study. Crit Care Med 45:6 (2017), 972–979.
53. Latronico, N, Herridge, M, Hopkins, RO, Angus, D, Hart, N, Hermans, G, et al. The ICM research agenda on intensive care unit-acquired weakness. Int Care Med 43:9 (2017), 1270–1281.
54. Schutte, CM, van der Meyden, CH, van Niekerk, L, Kakaza, M, van Coller, R, Ueckermann, V, et al. Severe porphyric neuropathy – importance of screening for porphyria in Guillain–Barré syndrome. S Afr Med J 106:1 (2015), 44–47.
55. Jacob, S, Damian, MS, Rajabally, Y, Charcot–Marie–Tooth disease type 1A associated with acute porphyric neuropathy. Eur J Neurol 14 (2007), e10–e11.
56. Connolly, S, Galvin, M, Hardiman, O, End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol 14:4 (2015), 435–442.
57. Hogden, A, Foley, G, Henderson, RD, James, N, Aoun, SM, Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc 10 (2017), 205–215.
58. Radunovic, A, Annane, D, Jewitt, K, Mustfa, N, Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev(4), 2009, CD004427.
59. Burkhardt, C, Neuwirth, C, Sommacal, A, Andersen, PM, Weber, M, Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One, 12(5), 2017, e0177555.
60. Kimura, F, Tracheostomy and invasive mechanical ventilation in amyotrophic lateral sclerosis: decision-making factors and survival analysis. Rinsho Shinkeigaku 56:4 (2016), 241–247.
61. Spataro, R, Bono, V, Marchese, S, La Bella, V, Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis. J Neurol Sci 323:1–2 (2012), 66–70.
62. Heritier Barras, AC, Adler, D, Iancu Ferfoglia, R, Ricou, B, Gasche, Y, Leuchter, I, et al. Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group. Swiss Med Wkly, 143, 2013, w13830.
63. Miller, RG, Jackson, CE, Kasarskis, EJ, England, JD, Forshew, D, Johnston, W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:15 (2009), 1218–1226.
64. Motor neurone disease: Assessment and management. NICE guideline Published online 24 February 2016 http://www.nice.org.uk/guidance/ng42.
65. Danel-Brunaud, V, Touzet, L, Chevalier, L, Moreau, C, Devos, D, Vandoolaeghe, S, et al. Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: a review. Rev Neurol (Paris) 173:5 (2017), 300–307.
66. Choi, SJ, Hong, YH, Shin, JY, Yoon, BN, Sohn, SY, Park, CS, et al. Takotsubo cardiomyopathy in amyotrophic lateral sclerosis. J Neurol Sci 375 (2017), 289–293.
67. Finsterer, J, Stöllberger, C, Takotsubo in amyotrophic lateral sclerosis. J Neurol Sci 379 (2017), 339–340.
68. Sperfeld, AD, Hanemann, CO, Ludolph, AC, Kassubek, J, Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 64:4 (2005), 753–754.
69. Chaouch, A, Beeson, D, Hantaï D, Lochmüller, H, 186th ENMC international workshop: congenital myasthenic syndromes 24–26 June 2011, Naarden, The Netherlands. Neuromuscul Disord 22:6 (2012), 566–576.
70. Wang, CH, Dowling, JJ, North, K, Schroth, MK, Sejersen, T, Schapiro, F, et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol 27:3 (2012), 363–382.
71. Gibbs, EM, Clarke, NF, Rose, K, Oates, EC, Webster, R, Feldman, EL, et al. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med 91:6 (2013), 727–737.
72. Naddaf, E, Milone, M, Hereditary myopathies with early respiratory insufficiency in adults. Muscle Nerve 56:5 (2017), 881–886.
73. van der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ, et al. A randomised study of alglucosidase alfa in late onset Pompe's disease. New Eng J Med 362:15 (2010), 1396–1406.
74. Schoser, B, Stewart, A, Kanters, S, Hamed, A, Jansen, J, Chan, K, et al. Survival and long-term outcomes in late-onset Pompe disease following algucosidase alpha treatment: a systematic review and meta-analysis. J Neurol 264:4 (2017), 621–630.
75. Palmio, J, Evila, A, Chapon, F, Tasca, G, Xiang, F, Brådvik, B, et al. Hereditary myopathy with early respiratory failure: occurrence in various populations. JNNP 85:3 (2014), 345–353.
76. Pfeffer, G, Elliott, HR, Griffin, H, Barresi, R, Miller, J, Marsh, J, et al. Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain 135:Pt 6 (2012), 1695–1713.
77. Lange, S, Edstrom, L, Udd, B, Gautel, M, Hereditary myopathy with early respiratory failure is caused by mutations in the Titin FN3 119 domain. Brain, 137, 2014, 279.
78. Selcen, D, Myofibrillar myopathies. Neuromuscul Disord 21:3 (2011), 161–171.
79. Foroud, T, Pankratz, N, Batchman, AP, Pauciulo, MW, Vidal, R, Miravalle, L, et al. A mutation in myotilin causes spheroid body myopathy. Neurology 65:12 (2005), 1936–1940.
80. Tasca, G, Udd, B, Hereditary myopathy with early respiratory failure (HMERF): still rare, but common enough. Neuromuscul Disord 28:3 (2018), 268–276.
81. Selcen, D., Engel, A.G, Mutations in myotilin cause myofibrillar myopathy. Neurology 62 (2004), 1363–1371.
82. Olivé M, Odgerel, Z, Martínez, A, Poza, JJ, Bragado, FG, Zabalza, RJ, et al. Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul Disord 21:8 (2011), 533–542.
83. Schade van Westrum, SM, Dekker, LR, de Voogt, WG, Wilde, AA, Ginjaar, IB, de Visser, M, van der Kooi, AJ, Cardiac involvement in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study. Muscle Nerve 50:6 (2014), 909–913.
84. Wahbi, K, Meune, C, Hamoudael, H, Stojkovic, T, Laforêt, P, Bécane, HM, Eymard, B, Duboc, D, Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul Disord 18:8 (2008), 650–655.
85. Nakanishi, T, Sakauchi, M, Kaneda, Y, Tomimatsu, H, Saito, K, Nakazawa, M, Osawa, M, Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics 117:6 (2006), e1187–e1192.
86. Uruha, A, Benveniste, O, Sporadic late onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Curr Opin Neurol 30:5 (2017), 457–463.
87. Schnitzler, LJ, Schreckenbach, T, Nadaj-Pakleza, A, Stenzel, W, Rushing, EJ, Van Damme, P, et al. Sporadic late onset Nemaline myopathy: clinicopathological characteristics and review of 76 cases. Orphanet J Rare Dis, 12(1), 2017, 86.
88. Bassez, G, Lazarus, A, Desguerre, I, Varin, J, Laforêt, P, Bécane, HM, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurol 63:10 (2004), 1939–1941.
89. Finsterer, J, Stöllberger, C, Maeztu, C, Sudden cardiac death in neuromuscular disorders. Int J Cardiol 203 (2016), 508–515, 10.1016/j.ijcard.2015.10.176.
90. Charron, P, Arbustini, E, Bonne, G, What should the cardiologist know about Lamin disease?. Arrhythm Electrophysiol Rev 1:1 (2012), 22–28.
91. Levraut, J1, Grimaud, D, Treatment of metabolic acidosis. Curr Opin Crit Care 9:4 (2003), 260–265.
92. Stewart, JD, Horvath, R, Baruffini, E, Ferrero, I, Bulst, S, Watkins, PB, Fontana, RJ, Day, CP, Chinnery, PF, Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52:5 (2010), 1791–1796.
93. Krähenbühl, S1, Brandner, S, Kleinle, S, Liechti, S, Straumann, D, Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20:4 (2000), 346–348.
94. Cope TE1, McFarland, R, Schaefer, A, Rapid-onset, linezolid-induced lactic acidosis in MELAS. Mitochondrion 11:6 (2011), 992–993.
95. Finsterer, J, Frank, M, Propofol is mitochondrion-toxic and may unmask a mitochondrial disorder. J Child Neurol 31:13 (2016), 1489–1494.
96. Danhauser, K, Smeitink, JA, Freisinger, P, Sperl, W, Sabir, H, Hadzik, B, Mayatepek, E, Morava, E, Distelmaier, F, Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease. J Inherit Metab Dis 38:3 (2015), 467–475.
97. Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L, et al. DMD care considerations working group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9:2 (2010), 177–189.
98. Pedrocchi, A, Ferrante, S, Ambrosini, E, Gandolla, M, Casellato, C, Schauer, T, et al. MUNDUS project: MUltimodal neuroprosthesis for daily upper limb support. J Neuroeng Rehabil, 10, 2013, 66.
99. Gandolla, M, Costa, A, Aquilante, L, Gfoehler, M, Puchinger, M, Braghin, F, et al. BRIDGE – behavioural reaching interfaces during daily antigravity activities through upper limb exoskeleton: preliminary results. IEEE Int Conf Rehabil Robot, 2017, 1007–1012.
100. Wu, RS, Gupta, S, Brown, RN, Yancy, CW, Wald, JW, Kaiser, P, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transpl 29:4 (2010), 432–438 Epub 2009 Oct 28.
101. Stoller, D, Araj, F, Amin, A, Fitzsimmons, C, Morlend, R, Thibodeau, JT, et al. Implantation of a left ventricular assist device to provide long-term support for end-stage Duchenne muscular dystrophy-associated cardiomyopathy. ESC Heart Fail 4:3 (2017), 379–383.
102. Gurnaney, H, Brown, A, Litman, RS, Malignant hyperthermia and muscular dystrophies. Anesth Analg 109:4 (2009), 1043–1048.